menu

Preventive PCI versus only optimal medical therapy for vulnerable plaques

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Preventive PCI versus optimal medical therapy only for vulnerable plaques

Marc Bonaca at the ACC24
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    ACC.24 - In the PREVENT trial, preventive PCI plus optimal medical therapy (OMT) was superior to OMT alone for reducing cardiac events in patients with non–flow-limiting vulnerable coronary plaques. Marc Bonaca, the discussant of the PREVENT trial, reviews the results.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Marc Bonaca, MD is a Cardiologist and Vascular Medicine Specialist and is the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado, Boulder, CO, US.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of PREVENT

    Release date: 15 april 2024

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    ACC.24 - In the PREVENT trial, preventive PCI plus optimal medical therapy (OMT) was superior to OMT alone for reducing cardiac events in patients with non–flow-limiting vulnerable coronary plaques. Marc Bonaca, the discussant of the PREVENT trial, reviews the results.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Marc Bonaca, MD is a Cardiologist and Vascular Medicine Specialist and is the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado, Boulder, CO, US.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of PREVENT

    Release date: 15 april 2024

Facebook Comments

Schedule24 May 2024